110 results on '"Valverde, Claudia"'
Search Results
2. A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
- Author
-
Pantaleo, Maria A., Heinrich, Michael C., Italiano, Antoine, Valverde, Claudia, Schöffski, Patrick, Grignani, Giovanni, Reyners, Anna K. L., Bauer, Sebastian, Reichardt, Peter, Stark, Daniel, Berhanu, Ghimja, Brandt, Ulrike, Stefanelli, Tommaso, and Gelderblom, Hans
- Published
- 2022
- Full Text
- View/download PDF
3. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
- Author
-
Martin-Broto, Javier, Redondo, Andres, Moura, David S., Valverde, Claudia, Morales, Jose Manuel, Lopez-Pousa, Antonio, Martinez-Trufero, Javier, Gutierrez, Antonio, Díaz-Beveridge, Roberto, Luna, Pablo, Martinez-Marin, Virginia, Marcilla, David, Arribas, Ivan, Ledesma, Patricio, Lopez-Martin, Jose Antonio, Di Lernia, Davide, Zamora, Jorge, and Hindi, Nadia
- Published
- 2022
- Full Text
- View/download PDF
4. Genomic Profiling and Clinical Outcomes of Targeted Therapies in Adult Patients with Soft Tissue Sarcomas
- Author
-
Kokkali, Stefania, primary, Georgaki, Eleni, additional, Mandrakis, Georgios, additional, Valverde, Claudia, additional, and Theocharis, Stamatios, additional
- Published
- 2023
- Full Text
- View/download PDF
5. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
- Author
-
Hernando-Calvo, Alberto, primary, Vila-Casadesús, Maria, additional, Bareche, Yacine, additional, Gonzalez-Medina, Alberto, additional, Abbas-Aghababazadeh, Farnoosh, additional, Lo Giacco, Deborah, additional, Martin, Agatha, additional, Saavedra, Omar, additional, Brana, Irene, additional, Vieito, Maria, additional, Fasani, Roberta, additional, Stagg, John, additional, Mancuso, Francesco, additional, Haibe-Kains, Benjamin, additional, Han, Ming, additional, Berche, Roger, additional, Pugh, Trevor J., additional, Mirallas, Oriol, additional, Jimenez, Jose, additional, Gonzalez, Nadia Saoudi, additional, Valverde, Claudia, additional, Muñoz-Couselo, Eva, additional, Suarez, Cristina, additional, Diez, Marc, additional, Élez, Elena, additional, Capdevila, Jaume, additional, Oaknin, Ana, additional, Saura, Cristina, additional, Macarulla, Teresa, additional, Galceran, Joan Carles, additional, Felip, Enriqueta, additional, Dienstmann, Rodrigo, additional, Bedard, Philippe L., additional, Nuciforo, Paolo, additional, Seoane, Joan, additional, Tabernero, Josep, additional, Garralda, Elena, additional, and Vivancos, Ana, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)
- Author
-
Pérez-Fidalgo, José Alejandro, Ortega, Eugenia, Ponce, Jordi, Redondo, Andrés, Sevilla, Isabel, Valverde, Claudia M., Isern-Verdum, Josep, Álava, Enrique de, Galera López, Mar, Marquina, Gloria, Sebio, Ana, Pérez-Fidalgo, José Alejandro, Ortega, Eugenia, Ponce, Jordi, Redondo, Andrés, Sevilla, Isabel, Valverde, Claudia M., Isern-Verdum, Josep, Álava, Enrique de, Galera López, Mar, Marquina, Gloria, and Sebio, Ana
- Abstract
Uterine sarcomas are very infrequent and heterogeneous entities. Due to its rarity, pathological diagnosis, surgical management, and systemic treatment are challenging. Treatment decision process in these tumors should be taken in a multidisciplinary tumor board. Available evidence is low and, in many cases, based on case series or clinical trials in which these tumors have been included with other soft tissue sarcoma. In these guidelines, we have tried to summarize the most relevant evidence in the diagnosis, staging, pathological disparities, surgical management, systemic treatment, and follow-up of uterine sarcomas.
- Published
- 2023
7. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco M., Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna C., Menso, María M., Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan A., George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Published
- 2020
- Full Text
- View/download PDF
8. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)
- Author
-
Pérez-Fidalgo, Jose Alejandro, primary, Ortega, Eugenia, additional, Ponce, Jordi, additional, Redondo, Andres, additional, Sevilla, Isabel, additional, Valverde, Claudia, additional, Isern Verdum, Josep, additional, de Alava, Enrique, additional, Galera López, Mar, additional, Marquina, Gloria, additional, and Sebio, Ana, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Working to improve the management of sarcoma patients across Europe: a policy checklist
- Author
-
Kasper, Bernd, Lecointe-Artzner, Estelle, Wait, Suzanne, Boldon, Shannon, Wilson, Roger, Gronchi, Alessandro, Valverde, Claudia, Eriksson, Mikael, Dumont, Sarah, Drove, Nora, Kanli, Athanasia, and Wartenberg, Markus
- Published
- 2018
- Full Text
- View/download PDF
10. Predictive value of MRP-1 in localized high-risk soft tissue sarcomas: a translational research associated to ISG-STS 1001 randomized phase III trial.
- Author
-
Martín-Broto, Javier, primary, Lopez-Alvarez, Maria, additional, Moura, David S, additional, Ramos, Rafael, additional, Collini, Paola, additional, Romagosa, Cleofe, additional, Bagué, Silvia, additional, Renne, Salvatore L, additional, Barisella, Marta, additional, Vélasco, Valérie, additional, Coindre, Jean-Michel, additional, Lopez-Lopez, Daniel, additional, Dopazo, Joaquin, additional, Gambarotti, Marco, additional, Braglia, Luca, additional, Merlo, Domenico Franco, additional, Palmerini, Emanuela, additional, Stacchiotti, Silvia, additional, Quagliuolo, Vittorio L, additional, Lopez-Pousa, Antonio, additional, Grignani, Giovanni, additional, Blay, Jean-Yves, additional, Brunello, Antonella, additional, Gutierrez, Antonio, additional, Valverde, Claudia, additional, Hindi, Nadia, additional, Dei Tos, Angelo Paolo, additional, Picci, Piero, additional, Casali, Paolo G, additional, and Gronchi, Alessandro, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trialmm
- Author
-
European Commission, Cancer Research UK, Associazione Italiana per la Ricerca sul Cancro, Fundación Científica Asociación Española Contra el Cáncer, Martín-Broto, Javier, López-Álvarez, María, Moura, David S., Ramos, Rafael, Collini, Paola, Romagosa, Cleofe, Bagué, Silvia, Renne, Salvatore L., Barisella, Marta, Velasco, Valerie, Coindre, Jean-Michel, López-López, Daniel, Dopazo, Joaquín, Gambarotti, Marco, Braglia, Luca, Merlo, Domenico Franco, Palmerini, Emanuela, Stacchiotti, Silvia, Quagliuolo, Vittorio L., López-Pousa, Antonio, Grignani, Giovanni, Blay, Jean-Yves, Brunello, Antonella, Gutiérrez, Antonio, Valverde, Claudia M., Hindi, Nadia, Dei Tos, Angelo Paolo, Picci, Piero, Casali, Paolo G., Gronchi, Alesandro, European Commission, Cancer Research UK, Associazione Italiana per la Ricerca sul Cancro, Fundación Científica Asociación Española Contra el Cáncer, Martín-Broto, Javier, López-Álvarez, María, Moura, David S., Ramos, Rafael, Collini, Paola, Romagosa, Cleofe, Bagué, Silvia, Renne, Salvatore L., Barisella, Marta, Velasco, Valerie, Coindre, Jean-Michel, López-López, Daniel, Dopazo, Joaquín, Gambarotti, Marco, Braglia, Luca, Merlo, Domenico Franco, Palmerini, Emanuela, Stacchiotti, Silvia, Quagliuolo, Vittorio L., López-Pousa, Antonio, Grignani, Giovanni, Blay, Jean-Yves, Brunello, Antonella, Gutiérrez, Antonio, Valverde, Claudia M., Hindi, Nadia, Dei Tos, Angelo Paolo, Picci, Piero, Casali, Paolo G., and Gronchi, Alesandro
- Abstract
MRP-1 is implicated in multidrug resistance and was described as prognostic in high-risk patients with soft-tissue sarcoma (STS) in a previous study. The current research aimed to validate MRP-1 prognostic/predictive value in localized sarcomas treated with anthracyclines plus ifosfamide within the ISG-1001 phase III study. In addition, the inhibitory activity on MRP-1 was investigated in preclinical studies to identify new combinations able to increase the efficacy of standard chemotherapy in STS. MRP-1 expression was assessed by IHC in tissue microarrays from patients with STS and tested for correlation with disease-free survival (DFS) and overall survival (OS). In vitro studies tested the efficacy of MRP-1 inhibitors (nilotinib, ripretinib, selumetinib, and avapritinib) in sarcoma cell lines. The effect of combinations of the most active MRP-1 inhibitors and chemotherapy was measured on the basis of apoptosis. MRP-1 was evaluable in 231 of 264 cases who entered the study. MRP-1 expression (strong intensity) was independently associated with worse DFS [HR, 1.78; 95% confidence interval (CI), 1.11–2.83; P = 0.016], in the multivariate analysis, with a trend for a worse OS (HR, 1.78; 95% CI, 0.97–3.25; P = 0.062). In vitro studies showed that the addition of MRP-1 inhibitors (nilotinib or avapritinib) to doxorubicin plus palifosfamide, significantly increased cell death in SK-UT-1 and CP0024 cell lines. MRP-1 is an adverse predictive factor in localized high-risk patients with STS treated with neoadjuvant anthracyclines plus ifosfamide followed by surgery. In vitro findings support the clinical assessment of the combination of chemotherapy and MRP-1 inhibitors as a promising strategy to overcome the drug ceiling effect for chemotherapy.
- Published
- 2021
12. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor
- Author
-
Fundación Mari Paz Jiménez Casado, Fundación Fero, Sociedad Española de Oncología Médica, Instituto de Salud Carlos III, European Commission, Secretaría de Educación Superior, Ciencia, Tecnología e Innovación (Ecuador), García-Valverde, Alfonso, Rosell, Jordi, Sayols, Sergi, Gómez-Peregrina, David, Pilco-Janeta, Daniel F., Olivares-Rivas, Iván, Álava, Enrique de, Maurel, Joan, Rubió-Casadevall, Jordi, Esteve-Codina, Anna, Gut, Marta, Valverde, Claudia M., Barretina, Jordi, Carles, Joan, Demetri, George D., Fletcher, Jonathan A., Arribas, Joaquín, Serrano, César, Fundación Mari Paz Jiménez Casado, Fundación Fero, Sociedad Española de Oncología Médica, Instituto de Salud Carlos III, European Commission, Secretaría de Educación Superior, Ciencia, Tecnología e Innovación (Ecuador), García-Valverde, Alfonso, Rosell, Jordi, Sayols, Sergi, Gómez-Peregrina, David, Pilco-Janeta, Daniel F., Olivares-Rivas, Iván, Álava, Enrique de, Maurel, Joan, Rubió-Casadevall, Jordi, Esteve-Codina, Anna, Gut, Marta, Valverde, Claudia M., Barretina, Jordi, Carles, Joan, Demetri, George D., Fletcher, Jonathan A., Arribas, Joaquín, and Serrano, César
- Abstract
KIT/PDGFRA oncogenic tyrosine kinase signaling is the central oncogenic event in most gastrointestinal stromal tumors (GIST), which are human malignant mesenchymal neoplasms that often feature myogenic differentiation. Although targeted inhibition of KIT/PDGFRA provides substantial clinical benefit, GIST cells adapt to KIT/PDGFRA driver suppression and eventually develop resistance. The specific molecular events leading to adaptive resistance in GIST remain unclear. By using clinically representative in vitro and in vivo GIST models and GIST patients’ samples, we found that the E3 ubiquitin ligase Atrogin-1 (FBXO32)—the main effector of muscular atrophy in cachexia—resulted in the most critical gene derepressed in response to KIT inhibition, regardless the type of KIT primary or secondary mutation. Atrogin-1 in GISTs is transcriptionally controlled by the KIT-FOXO3a axis, thus indicating overlap with Atrogin-1 regulation mechanisms in nonneoplastic muscle cells. Further, Atrogin-1 overexpression was a GIST-cell-specific pro-survival mechanism that enabled the adaptation to KIT-targeted inhibition by apoptosis evasion through cell quiescence. Buttressed on these findings, we established in vitro and in vivo the preclinical proof-of-concept for co-targeting KIT and the ubiquitin pathway to maximize the therapeutic response to first-line imatinib treatment.
- Published
- 2021
13. A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin
- Author
-
Grupo Español de Investigación en Sarcomas, PharmaMar, Instituto de Salud Carlos III, Moura, David S., Peña-Chilet, María, Cordero Varela, Juan Antonio, Álvarez-Alegret, Ramiro, Agra-Pujol, Carolina, Izquierdo, Francisco, Ramos, Rafael, Ortega-Medina, Luis, Martín-Dávila, Francisco, Castilla, Carolina, Hernández-León, Carmen Nieves, Romagosa, Cleofe, Vaz Salgado, María Ángeles, Lavernia, Javier, Bagué, Silvia, Mayordomo-Aranda, Empar, Vicioso, Luis, Hernández Barceló, José Emilio, Rubió-Casadevall, Jordi, Juan, Ana de, Fiaño-Valverde, María Concepción, Hindi, Nadia, López-Álvarez, María, Lacerenza, Serena, Dopazo, Joaquín, Gutiérrez, Antonio, Álvarez, Rosa, Valverde, Claudia M., Martínez-Trufero, Javier, Martín-Broto, Javier, Grupo Español de Investigación en Sarcomas, PharmaMar, Instituto de Salud Carlos III, Moura, David S., Peña-Chilet, María, Cordero Varela, Juan Antonio, Álvarez-Alegret, Ramiro, Agra-Pujol, Carolina, Izquierdo, Francisco, Ramos, Rafael, Ortega-Medina, Luis, Martín-Dávila, Francisco, Castilla, Carolina, Hernández-León, Carmen Nieves, Romagosa, Cleofe, Vaz Salgado, María Ángeles, Lavernia, Javier, Bagué, Silvia, Mayordomo-Aranda, Empar, Vicioso, Luis, Hernández Barceló, José Emilio, Rubió-Casadevall, Jordi, Juan, Ana de, Fiaño-Valverde, María Concepción, Hindi, Nadia, López-Álvarez, María, Lacerenza, Serena, Dopazo, Joaquín, Gutiérrez, Antonio, Álvarez, Rosa, Valverde, Claudia M., Martínez-Trufero, Javier, and Martín-Broto, Javier
- Abstract
Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. The majority of these studies only focused on specific factors (ERCC1, ERCC5, and BRCA1) and did not evaluate several other DDR-related genes that could have a relevant role for trabectedin efficacy. In this retrospective translational study, 118 genes involved in DDR were evaluated to determine, by transcriptomics, a predictive gene signature of trabectedin efficacy. A six-gene predictive signature of trabectedin efficacy was built in a series of 139 tumor samples from patients with advanced STS. Patients in the high-risk gene signature group showed a significantly worse progression-free survival compared with patients in the low-risk group (2.1 vs 6.0 months, respectively). Differential gene expression analysis defined new potential predictive biomarkers of trabectedin sensitivity (PARP3 and CCNH) or resistance (DNAJB11 and PARP1). Our study identified a new gene signature that significantly predicts patients with higher probability to respond to treatment with trabectedin. Targeting some genes of this signature emerges as a potential strategy to enhance trabectedin efficacy.
- Published
- 2021
14. A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin
- Author
-
Moura, David S., primary, Peña‐Chilet, Maria, additional, Cordero Varela, Juan Antonio, additional, Alvarez‐Alegret, Ramiro, additional, Agra‐Pujol, Carolina, additional, Izquierdo, Francisco, additional, Ramos, Rafael, additional, Ortega‐Medina, Luis, additional, Martin‐Davila, Francisco, additional, Castilla‐Ramirez, Carolina, additional, Hernandez‐Leon, Carmen Nieves, additional, Romagosa, Cleofe, additional, Vaz Salgado, Maria Angeles, additional, Lavernia, Javier, additional, Bagué, Silvia, additional, Mayodormo‐Aranda, Empar, additional, Vicioso, Luis, additional, Hernández Barceló, Jose Emilio, additional, Rubio‐Casadevall, Jordi, additional, de Juan, Ana, additional, Fiaño‐Valverde, Maria Concepcion, additional, Hindi, Nadia, additional, Lopez‐Alvarez, Maria, additional, Lacerenza, Serena, additional, Dopazo, Joaquin, additional, Gutierrez, Antonio, additional, Alvarez, Rosa, additional, Valverde, Claudia, additional, Martinez‐Trufero, Javier, additional, and Martín‐Broto, Javier, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic
- Author
-
Martín-Broto, Javier, Hindi, Nadia, Aguiar Júnior, Samuel, Badilla-González, Ronald, Castro-Oliden, Victor, Chacón, Matias, Correa-Generoso, Raquel, de Álava, Enrique, Donati, Davide María, Eriksson, Mikael, Falla-Jimenez, Martin, German, Gisela, Gobo Silva, Maria Leticia, Gouin, Francois, Gronchi, Alessandro, Haro-Varas, Juan, Jiménez-Brenes, Natalia, Lopes de Mello, Celso Abdon, Kasper, Bernd, Maki, Robert, Martínez-Delgado, Paula, Martínez-Said, Hector, Martinez-Tlahuel, Jorge Luis, Morales-Pérez, Jose Manuel, Muñoz-Casares, Francisco Cristobal, Nakagawa, Suely A., Ortiz-Cruz, Eduardo Jose, Palmerini, Emanuela, Patel, Shreyaskumar, Moura, David S., Stacchiotti, Silvia, Sunyach, Marie Pierre, Valverde, Claudia M., Waisberg, Federico, Blay, Jean-Yves, Universitat Autònoma de Barcelona, European Commission, Martin‐Broto, Javier, [Martin-Broto,J, Hindi,N, Martínez-Delgado,P, Moura,DS] Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain. [Martin-Broto,J, Hindi,N] Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain. [Aguiar Jr,S] Department of Pelvic Surgery, A.C. Camargo Cancer Center, São Paulo, Brazil. [Badilla-González,R] Department of medical oncology, Rafael Ángel Calderón Guardia Hospital, San José, Costa Rica. [Castro-Oliden,V, Haro-Varas,JC] Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. [Chacón,M, Waisberg,F] Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina. [Correa-Generoso,R] 7 Radiotherapy Department, Virgen de la Victoria University Hospital, Málaga, Spain. [de Álava,E] Pathology Department, University Hospital Virgen del Rocío, Seville, Spain. [de Álava,E] CIBERONC, Madrid, Spain. [de Álava,E] Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, Spain. [Donati,DM] Unit of Orthopedic Pathology and Osteoarticular Tissue Regeneration, Rizzoli Orthopedic Institute, Bologna, Italy. [Eriksson,E] Department of Medical Oncology, Skane University Hospital-Lund, Lund, Sweden. [Falla-Jimenez,M]Department of Breast and Soft Tissues Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. [German,G] Department of Medical Oncology, Hospital Oncológico Provincial, Córdoba, Argentina. [Gobo Silva,ML] Department of Radiation Therapy, A.C. Camargo Cancer Center, São Paulo, Brazil. [Gouin,F] Department of Orthopedic Surgery, Centre León Bérard, Lyon, France. [Gronchi,A] Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy. [Jiménez-Brenes,N] Department of Medical Oncology, San Vicente de Paúl Hospital, Heredia, Costa Rica. [Kasper,B] Department of Medical Oncology, Mannheim University Medical Center, Mannheim, Germany. [Lopes de Mello,CA] Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil. [Maki,R] Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. [Martínez-Said,H] Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico. [Martinez-Tlahuel,JL] Department of Surgery, Instituto Nacional de Cancerología, Mexico City, Mexico. [Morales-Pérez,JM] Radiology Department, University Hospital Virgen del Rocio, Seville, Spain. [Muñoz-Casares,FC] Department of Surgery, University Hospital Virgen del Rocio, Seville, Spain. [Nakagawa,SA] Department of Orthopedics, A.C. Camargo Cancer Center, São Paulo, Brazil. [Ortiz-Cruz,EJ] Orthopedic Surgery and Traumatology Department, La Paz University Hospital, Madrid, Spain. [Palmerini,E] Department of Medical Oncology, Rizzoli Orthopedic Institute, Bologna, Italy. [Patel,S] Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. [Stacchiotti,S] Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy. [Sunyach,MP] Department of Radiation Therapy, Centre León Bérard, Lyon, France. [Valverde,CM] Department of Medical Oncology, Vall d'Hebron Hospital, Barcelona, Spain.[Blay,JY] Department of Medical Oncology, Centre León Bérard, Lyon, France., SELNET has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825806., Martin‐Broto, Javier [0000-0001-7350-6916], Martin-Broto J., Hindi N., Aguiar S., Badilla-Gonzalez R., Castro-Oliden V., Chacon M., Correa-Generoso R., de Alava E., Donati D.M., Eriksson M., Falla-Jimenez M., German G., Gobo Silva M.L., Gouin F., Gronchi A., Haro-Varas J.C., Jimenez-Brenes N., Kasper B., Lopes de Mello C.A., Maki R., Martinez-Delgado P., Martinez-Said H., Martinez-Tlahuel J.L., Morales-Perez J.M., Munoz-Casares F.C., Nakagawa S.A., Ortiz-Cruz E.J., Palmerini E., Patel S., Moura D.S., Stacchiotti S., Sunyach M.P., Valverde C.M., Waisberg F., and Blay J.-Y.
- Subjects
Prioritization ,Cancer Research ,medicine.medical_specialty ,Consensus ,Latin Americans ,Coronavirus disease 2019 (COVID-19) ,Guideline ,Guidelines ,Patient care ,Medical Oncology ,Health Care::Health Services Administration::Patient Care Management::Patient Care Team [Medical Subject Headings] ,Geographical Locations::Geographic Locations::Americas::Latin America [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,03 medical and health sciences ,0302 clinical medicine ,Organisms::Viruses::RNA Viruses::Nidovirales::Coronaviridae [Medical Subject Headings] ,COVID‐19 ,Multidisciplinary approach ,Pandemic ,Atención al paciente ,Humans ,Medicine ,030212 general & internal medicine ,Directrices para la planificación en salud ,Precautionary principle ,Multidisciplinary ,SARS-CoV-2 ,business.industry ,Sarcomas ,Health Care::Environment and Public Health::Public Health::Disease Outbreaks::Epidemics::Pandemics [Medical Subject Headings] ,COVID-19 ,Sarcoma ,Health Care::Health Care Economics and Organizations::Organizations::Congresses as Topic::Consensus Development Conferences as Topic [Medical Subject Headings] ,medicine.disease ,Health Care::Health Care Economics and Organizations::Health Planning::Health Planning Guidelines [Medical Subject Headings] ,3. Good health ,Europe ,Latin America ,Oncology ,030220 oncology & carcinogenesis ,Scale (social sciences) ,Family medicine ,Practice Guidelines as Topic ,Guías como asunto ,Geographical Locations::Geographic Locations::Europe [Medical Subject Headings] ,business - Abstract
This article also appears in: COVID-19 and Cancer Article Collection., [Background] The COVID‐19 outbreak has resulted in collision between patients infected with SARS‐CoV‐2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID‐19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care. The Sarcoma European‐Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID‐19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID‐19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower‐priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology‐Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID‐19 outbreak., [Material and Methods] A total of 125 recommendations were proposed in soft‐tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2–3 months, respectively. The consensus level for each recommendation was classified as “strongly recommended” (SR) if more than 90% of experts agreed, “recommended” (R) if 75%–90% of experts agreed and “no consensus” (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European‐Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology‐Magnitude of clinical benefit scale was applied to systemic‐treatment recommendations to support prioritization., [Results] There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher‐priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower‐priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively)., [Conclusion] The consensus on 115 of 125 recommendations indicates a high‐level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID‐19 outbreak. Implications for Practice, The authors would like to thank the SELNET project. SELNET has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825806.
- Published
- 2020
16. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
- Author
-
Lostes-Bardaji, M. Julia, primary, García-Illescas, David, additional, Valverde, Claudia, additional, and Serrano, César, additional
- Published
- 2021
- Full Text
- View/download PDF
17. The sacral chordoma margin
- Author
-
Radaelli, Stefano, Fossati, P., Stacchiotti, Silvia, Akiyama, T., Asencio, J. M., Bandiera, S., Boglione, A., Boland, P., Bolle, S., Bruland, Ø., Brunello, Antonella, Bruzzi, Paolo, Campanacci, D., Cananzi, F., Capanna, R., Casadei, R., Cordoba, Abel, Court, C., Dei Tos, Angelo Paolo, Delaney, T., Paoli, A. de, Pas, T. M. de, Desai, A., Brina, L. di, Donati, Davide María, Fabbri, N., Fiore, M. R., Frezza, Anna M., Gambarotti, Marco, Gasbarrini, A., Georg, P., Grignani, Giovanni, Hindi, Nadia, Hug, E. B., Jones, Rebecca, Kawai, Akira, Krol, A. D., Grange, F. le, Luzzati, A., Marquina, G., Martin-Benlloch, J. A., Mazzocco, K., Navarria, F., Parchi, P. D., Patel, S., Pennacchioli, E., Petrongari, M. G., Picci, Piero, Pollock, R., Porcu, L., Quagliuolo, V., Sangalli, C., Scheipl, S., Scotto, G. M., Spalek, M., Steinmeier, T., Timmermann, B., Trama, A., Uhl, Matthias, Valverde, Claudia M., Varga, P. P., Verges, R., Weber, D. C., Zoccali, C., Casali, Paolo G., Sommer, J., and Gronchi, Alesandro
- Subjects
musculoskeletal diseases ,Radiation therapy ,Surgical margins ,Sacral chordoma ,Surgery - Abstract
[Objective]: Aim of the manuscript is to discuss how to improve margins in sacral chordoma. [Background]: Chordoma is a rare neoplasm, arising in half cases from the sacrum, with reported local failure in >50% after surgery. [Methods]: A multidisciplinary meeting of the “Chordoma Global Consensus Group” was held in Milan in 2017, focusing on challenges in defining and achieving optimal margins in chordoma with respect to surgery, definitive particle radiation therapy (RT) and medical therapies. This review aims to report on the outcome of the consensus meeting and to provide a summary of the most recent evidence in this field. Possible new ways forward, including on-going international clinical studies, are discussed. [Results]: En-bloc tumor-sacrum resection is the cornerstone of treatment of primary sacral chordoma, aiming to achieve negative microscopic margins. Radical definitive particle therapy seems to offer a similar outcome compared to surgery, although confirmation in comparative trials is lacking; besides there is still a certain degree of technical variability across institutions, corresponding to different fields of treatment and different tumor coverage. To address some of these questions, a prospective, randomized international study comparing surgery versus definitive high-dose RT is ongoing. Available data do not support the routine use of any medical therapy as (neo)adjuvant/cytoreductive treatment. [Conclusion]: Given the significant influence of margins status on local control in patients with primary localized sacral chordoma, the clear definition of adequate margins and a standard local approach across institutions for both surgery and particle RT is vital for improving the management of these patients.
- Published
- 2020
18. Additional file 1 of Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco, Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna, Menso, María, Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan, George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Abstract
Additional file 1: Table S1. Genes covered by VHIO amplicon-sequencing panel.
- Published
- 2020
- Full Text
- View/download PDF
19. Additional file 5 of Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco, Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna, Menso, María, Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan, George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Abstract
Additional file 5: Table S5. Association between clinicopathological factors and the presence of ctDNA in plasma.
- Published
- 2020
- Full Text
- View/download PDF
20. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
- Author
-
Martín Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Martínez Trufero, Javier, Redondo, Andrés, Valverde, Claudia, Encinas Tobajas, Víctor, Álava Casado, Enrique de, López Martín, José A., Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica, Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología, and Universidad de Sevilla. CTS1035: Patología Molecular del Cáncer Sólido
- Subjects
PD-1/ PD-L1 axis (nivolumab) ,Sarcomas ,Test the double inhibition of angiogenesis (sunitinib) ,PD-1 inhibitors ,Immune response - Abstract
Background: Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab). Methods: This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5mg daily from day 1, plus nivolumab 3mg/kg intravenously on day 15, and then every 2weeks; and level −1 with sunitinib 37.5mg on the first 14 days (induction) and then 25mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II). Results: From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5mg as induction and then 25mg in combination with nivolumab. After a median follow-up of 17months (4–26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3–4 adverse events included transaminitis (17.3%) and neutropenia (11.5%). Conclusions: Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6months. GEIS ISG BMS Pfizer
- Published
- 2020
21. Additional file 7 of Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco, Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna, Menso, María, Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan, George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Abstract
Additional file 7: Figure S7. Hematoxylin & eosin and c-KIT immunohistochemical stains for GIST cases 8 (A, B), 12 (C, D) and 10 (E, F) at baseline (A, C, E) and at the time of tumor progression (B, D, F), showing loss of c-KIT expression in the absence of resistance mutations.
- Published
- 2020
- Full Text
- View/download PDF
22. Additional file 2 of Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco, Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna, Menso, María, Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan, George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Abstract
Additional file 2: Table S2. Primers and sequences for ddPCR.
- Published
- 2020
- Full Text
- View/download PDF
23. Additional file 6 of Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco, Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna, Menso, María, Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan, George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Abstract
Additional file 6: Figure S6. Concordance of allele frequency between NGS and ddPCR for detection of plasma mutations in all plasma samples studied with both assays (A). ctDNA detection and allele frequencies distributed by samples detected only by ddPCR, NGS or both technologies.
- Published
- 2020
- Full Text
- View/download PDF
24. Additional file 8 of Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco, Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna, Menso, María, Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan, George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Abstract
Additional file 8: Figure S8. Schematic view of the resistance mechanisms found in our series by NGS of plasma and tissue, and histological evaluation. Mechanisms of resistance are grouped according to its determination by ctDNA evaluation or by tumor tissue sequencing or histological evaluation.
- Published
- 2020
- Full Text
- View/download PDF
25. Additional file 3 of Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco, Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna, Menso, María, Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan, George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Abstract
Additional file 3: Table S3. Known KIT exon 11 long/complex indels called with two different pipelines.
- Published
- 2020
- Full Text
- View/download PDF
26. Additional file 4 of Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judit, Mancuso, Francesco, Valverde, Claudia, Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna, Menso, María, Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan, George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Subjects
digestive system diseases - Abstract
Additional file 4: Table S4. Correlation of KIT/PDGFRA genotype between tissue and plasma.
- Published
- 2020
- Full Text
- View/download PDF
27. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
- Author
-
Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica, Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología, Universidad de Sevilla. CTS1035: Patología Molecular del Cáncer Sólido, Martín Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Martínez Trufero, Javier, Redondo, Andrés, Valverde, Claudia, Encinas Tobajas, Víctor, Álava Casado, Enrique de, López Martín, José A., Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica, Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología, Universidad de Sevilla. CTS1035: Patología Molecular del Cáncer Sólido, Martín Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Martínez Trufero, Javier, Redondo, Andrés, Valverde, Claudia, Encinas Tobajas, Víctor, Álava Casado, Enrique de, and López Martín, José A.
- Abstract
Background: Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab). Methods: This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5mg daily from day 1, plus nivolumab 3mg/kg intravenously on day 15, and then every 2weeks; and level −1 with sunitinib 37.5mg on the first 14 days (induction) and then 25mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II). Results: From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5mg as induction and then 25mg in combination with nivolumab. After a median follow-up of 17months (4–26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3–4 adverse events included transaminitis (17.3%) and neutropenia (11.5%). Conclusions: Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6months.
- Published
- 2020
28. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
- Author
-
Harvard University, Adelson Medical Research Foundation, National Institutes of Health (US), National Cancer Institute (US), Demetri, G. D., Antonescu, Cristina R., Bjerkehagen, B., Bovee, J. V. M. G., Boye, K., Chacón, Matias, Dei Tos, Angelo Paolo, Desai, Jayesh, Fletcher, Jonathan A., Gelderblom, Hans, George, Suzanne, Gronchi, Alesandro, Haas, R. L., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Judson, I., Kang, Y.-K., Kawai, Akira, Lazar, A. J., Cesne, Axel Le, Maestro, Roberta, Maki, Robert, Martín, J., Patel, S., Penault-Llorca, F., Premanand Raut, C., Rutkowski, Piotr, Safwat, A. A., Sbaraglia, Marta, Schaefer, I.-M., Shen, L., Serrano, C., Schöffski, P., Stacchiotti, Silvia, Sundby Hall, K., Tap, William D., Thomas, David M., Trent, J., Valverde, Claudia M., Graaf, W.T.A. van der, Mehren, M. von, Wagner, Andrew J., Wardelmann, Eva, Naito, Y., Zalcberg, J., Blay, Jean-Yves, Harvard University, Adelson Medical Research Foundation, National Institutes of Health (US), National Cancer Institute (US), Demetri, G. D., Antonescu, Cristina R., Bjerkehagen, B., Bovee, J. V. M. G., Boye, K., Chacón, Matias, Dei Tos, Angelo Paolo, Desai, Jayesh, Fletcher, Jonathan A., Gelderblom, Hans, George, Suzanne, Gronchi, Alesandro, Haas, R. L., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Judson, I., Kang, Y.-K., Kawai, Akira, Lazar, A. J., Cesne, Axel Le, Maestro, Roberta, Maki, Robert, Martín, J., Patel, S., Penault-Llorca, F., Premanand Raut, C., Rutkowski, Piotr, Safwat, A. A., Sbaraglia, Marta, Schaefer, I.-M., Shen, L., Serrano, C., Schöffski, P., Stacchiotti, Silvia, Sundby Hall, K., Tap, William D., Thomas, David M., Trent, J., Valverde, Claudia M., Graaf, W.T.A. van der, Mehren, M. von, Wagner, Andrew J., Wardelmann, Eva, Naito, Y., Zalcberg, J., and Blay, Jean-Yves
- Abstract
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new personalized therapies for a subset of patients with sarcoma in the form of tropomyosin receptor kinase (TRK) inhibitors. NTRK gene rearrangements and fusion transcripts can be detected with different molecular pathology techniques, while TRK protein expression can be demonstrated with immunohistochemistry. The rarity and diagnostic complexity of NTRK gene fusions raise a number of questions and challenges for clinicians. To address these challenges, the World Sarcoma Network convened two meetings of expert adult oncologists and pathologists and subsequently developed this article to provide practical guidance on the management of patients with sarcoma harboring NTRK gene fusions. We propose a diagnostic strategy that considers disease stage and histologic and molecular subtypes to facilitate routine testing for TRK expression and subsequent testing for NTRK gene fusions.
- Published
- 2020
29. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
- Author
-
Fundación Fero, Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, Fundació Privada Cellex, Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judith, Mancuso, Francesco M., Valverde, Claudia M., Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna C., Menso, María M., Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan A., George, Suzanne, Carles, Joan, Arribas, Joaquín, Fundación Fero, Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, Fundació Privada Cellex, Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judith, Mancuso, Francesco M., Valverde, Claudia M., Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna C., Menso, María M., Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan A., George, Suzanne, Carles, Joan, and Arribas, Joaquín
- Abstract
[Background] Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. Thus, circulating tumor (ct)DNA determination is expected to be an informative non-invasive dynamic biomarker in GIST patients., [Methods] We performed amplicon-based next-generation sequencing (NGS) across 60 clinically relevant genes in 37 plasma samples from 18 GIST patients collected prospectively. ctDNA alterations were compared with NGS of matched tumor tissue samples (obtained either simultaneously or at the time of diagnosis) and cross-validated with droplet digital PCR (ddPCR)., [Results] We were able to identify cfDNA mutations in five out of 18 patients had detectable in at least one timepoint. Overall, NGS sensitivity for detection of cell-free (cf)DNA mutations in plasma was 28.6%, showing high concordance with ddPCR confirmation. We found that GIST had relatively low ctDNA shedding, and mutations were at low allele frequencies. ctDNA was detected only in GIST patients with advanced disease after imatinib failure, predicting tumor dynamics in serial monitoring. KIT secondary mutations were the only mechanism of resistance found across 10 imatinib-resistant GIST patients progressing to sunitinib or regorafenib., [Conclusions] ctDNA evaluation with amplicon-based NGS detects KIT primary and secondary mutations in metastatic GIST patients, particularly after imatinib progression. GIST exhibits low ctDNA shedding, but ctDNA monitoring, when positive, reflects tumor dynamics.
- Published
- 2020
30. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
- Author
-
Grupo GEIS, Pfizer, Martín-Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Martínez-Trufero, Javier, Redondo, Andrés, Valverde, Claudia M., Stacchiotti, Silvia, López-Pousa, Antonio, D'Ambrosio, Lorenzo, Gutiérrez, Antonio, Pérez-Vega, Herminia, Encinas-Tobajas, Víctor, Álava, Enrique de, Collini, Paola, Peña-Chilet, María, Dopazo, Joaquín, Carrasco-García, Irene, López-Álvarez, María, Moura, David S., López-Martín, José A., Grupo GEIS, Pfizer, Martín-Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Martínez-Trufero, Javier, Redondo, Andrés, Valverde, Claudia M., Stacchiotti, Silvia, López-Pousa, Antonio, D'Ambrosio, Lorenzo, Gutiérrez, Antonio, Pérez-Vega, Herminia, Encinas-Tobajas, Víctor, Álava, Enrique de, Collini, Paola, Peña-Chilet, María, Dopazo, Joaquín, Carrasco-García, Irene, López-Álvarez, María, Moura, David S., and López-Martín, José A.
- Abstract
[Background] Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab)., [Methods] This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5 mg daily from day 1, plus nivolumab 3 mg/kg intravenously on day 15, and then every 2 weeks; and level −1 with sunitinib 37.5 mg on the first 14 days (induction) and then 25 mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression-free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II)., [Results] From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5 mg as induction and then 25 mg in combination with nivolumab. After a median follow-up of 17 months (4–26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3–4 adverse events included transaminitis (17.3%) and neutropenia (11.5%)., [Conclusions] Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months., [Trial registration number] NCT03277924.
- Published
- 2020
31. Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic
- Author
-
European Commission, Martín-Broto, Javier, Hindi, Nadia, Aguiar, Samuel, Badilla‐González, Ronald, Castro‐Oliden, Victor, Chacón, Matias, Correa‐Generoso, Raquel, Álava, Enrique de, Donati, Davide María, Eriksson, Mikael, Falla‐Jimenez, Martin, German, Gisela, Gobo Silva, Maria Leticia, Gouin, Francois, Gronchi, Alesandro, Haro‐Varas, Juan Carlos, Jiménez‐Brenes, Natalia, Kasper, Bernd, Lopes de Mello, Celso Abdon, Maki, Robert, Martínez-Delgado, Paula, Martínez‐Said, Héctor, Martinez‐Tlahuel, Jorge Luis, Morales‐Pérez, José Manuel, Muñoz‐Casares, Francisco Cristobal, Nakagawa, Suely A., Ortiz‐Cruz, Eduardo Jose, Palmerini, Emanuela, Patel, Shreyaskumar, Moura, David S., Stacchiotti, Silvia, Sunyach, Marie Pierre, Valverde, Claudia M., Waisberg, Federico, Blay, Jean-Yves, European Commission, Martín-Broto, Javier, Hindi, Nadia, Aguiar, Samuel, Badilla‐González, Ronald, Castro‐Oliden, Victor, Chacón, Matias, Correa‐Generoso, Raquel, Álava, Enrique de, Donati, Davide María, Eriksson, Mikael, Falla‐Jimenez, Martin, German, Gisela, Gobo Silva, Maria Leticia, Gouin, Francois, Gronchi, Alesandro, Haro‐Varas, Juan Carlos, Jiménez‐Brenes, Natalia, Kasper, Bernd, Lopes de Mello, Celso Abdon, Maki, Robert, Martínez-Delgado, Paula, Martínez‐Said, Héctor, Martinez‐Tlahuel, Jorge Luis, Morales‐Pérez, José Manuel, Muñoz‐Casares, Francisco Cristobal, Nakagawa, Suely A., Ortiz‐Cruz, Eduardo Jose, Palmerini, Emanuela, Patel, Shreyaskumar, Moura, David S., Stacchiotti, Silvia, Sunyach, Marie Pierre, Valverde, Claudia M., Waisberg, Federico, and Blay, Jean-Yves
- Abstract
[Background] The COVID‐19 outbreak has resulted in collision between patients infected with SARS‐CoV‐2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID‐19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care. The Sarcoma European‐Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID‐19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID‐19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower‐priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology‐Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID‐19 outbreak., [Material and Methods] A total of 125 recommendations were proposed in soft‐tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2–3 months, respectively. The consensus level for each recommendation was classified as “strongly recommended” (SR) if more than 90% of experts agreed, “recommended” (R) if 75%–90% of experts agreed and “no consensus” (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European‐Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology‐Magnitude of clinical benefit scale was applied to systemic‐treatment recommendations to support prioritization., [Results] There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher‐priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower‐priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively)., [Conclusion] The consensus on 115 of 125 recommendations indicates a high‐level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID‐19 outbreak. Implications for Practice
- Published
- 2020
32. Sarcoma European & Latin American Network (SELNET) recommendations on prioritization in sarcoma care during covid‐19 pandemic
- Author
-
Martin‐Broto, Javier [0000-0001-7350-6916], Martín-Broto, Javier, Hindi, Nadia, Aguiar, Samuel, Badilla‐González, Ronald, Castro‐Oliden, Victor, Chacón, Matias, Correa‐Generoso, Raquel, Álava, Enrique de, Donati, Davide María, Eriksson, Mikael, Falla‐Jimenez, Martin, German, Gisela, Gobo Silva, Maria Leticia, Gouin, Francois, Gronchi, Alesandro, Haro‐Varas, Juan Carlos, Jiménez‐Brenes, Natalia, Kasper, Bernd, Lopes de Mello, Celso Abdon, Maki, Robert, Pérez, Paula S., Muñoz‐Casares, Francisco Cristobal, Nakagawa, Suely A., Ortiz‐Cruz, Eduardo Jose, Palmerini, Emanuela, Patel, Shreyaskumar, Moura, David S., Stacchiotti, Silvia, Sunyach, Marie Pierre, Valverde, Claudia M., Waisberg, Federico, Blay, Jean-Yves, Martin‐Broto, Javier [0000-0001-7350-6916], Martín-Broto, Javier, Hindi, Nadia, Aguiar, Samuel, Badilla‐González, Ronald, Castro‐Oliden, Victor, Chacón, Matias, Correa‐Generoso, Raquel, Álava, Enrique de, Donati, Davide María, Eriksson, Mikael, Falla‐Jimenez, Martin, German, Gisela, Gobo Silva, Maria Leticia, Gouin, Francois, Gronchi, Alesandro, Haro‐Varas, Juan Carlos, Jiménez‐Brenes, Natalia, Kasper, Bernd, Lopes de Mello, Celso Abdon, Maki, Robert, Pérez, Paula S., Muñoz‐Casares, Francisco Cristobal, Nakagawa, Suely A., Ortiz‐Cruz, Eduardo Jose, Palmerini, Emanuela, Patel, Shreyaskumar, Moura, David S., Stacchiotti, Silvia, Sunyach, Marie Pierre, Valverde, Claudia M., Waisberg, Federico, and Blay, Jean-Yves
- Abstract
Background COVID‐19 outbreak has resulted in collision between SARS‐CoV‐2‐infected patients and cancer patients on different fronts. Serious SARS‐CoV‐2 cases overwhelmed hospital capacity, especially in intensive care units, causing a domino effect, displacing areas from their primary use. Cancer patient has been impacted by deferral, modification or even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle have been proposed for cancer care during COVID‐19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care. Material and methods A total of 125 recommendations were proposed in soft‐tissue, bone and visceral sarcoma care. Recommendations were assigned as higher‐ or lower‐priority if they cannot or can be postponed at least 2‐3 months, respectively. The consensus level for each recommendation was classified as “strongly recommended” (SR) if more than 90% of experts agreed, “recommended” (R) if 75‐90% of experts agreed and “no consensus” (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the SELNET consortium participated, including countries in the Americas and Europe. The ESMO‐Magnitude of clinical benefit scale was applied to systemic‐treatment recommendations to support prioritization. Results There were 80 SR, 35 R and 10 NC among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher‐priority recommendations (85%, 12% and 3% for SR, R and NC, respectively) than in the 50 lower‐priority recommendations (32%, 52% and 16% for SR, R and NC, respectively). Conclusion The consensus on 115 of 125 recommendations indicates a high‐level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID‐19 outbreak. The details of different recommendations and the distinction between two priority le
- Published
- 2020
33. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
- Author
-
Martin-Broto, Javier, primary, Hindi, Nadia, additional, Grignani, Giovanni, additional, Martinez-Trufero, Javier, additional, Redondo, Andres, additional, Valverde, Claudia, additional, Stacchiotti, Silvia, additional, Lopez-Pousa, Antonio, additional, D'Ambrosio, Lorenzo, additional, Gutierrez, Antonio, additional, Perez-Vega, Herminia, additional, Encinas-Tobajas, Victor, additional, de Alava, Enrique, additional, Collini, Paola, additional, Peña-Chilet, Maria, additional, Dopazo, Joaquin, additional, Carrasco-Garcia, Irene, additional, Lopez-Alvarez, Maria, additional, Moura, David S, additional, and Lopez-Martin, Jose A, additional
- Published
- 2020
- Full Text
- View/download PDF
34. Sarcoma European and Latin American Network ( SELNET ) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic
- Author
-
Martin‐Broto, Javier, primary, Hindi, Nadia, additional, Aguiar, Samuel, additional, Badilla‐González, Ronald, additional, Castro‐Oliden, Victor, additional, Chacón, Matias, additional, Correa‐Generoso, Raquel, additional, Álava, Enrique, additional, Donati, Davide María, additional, Eriksson, Mikael, additional, Falla‐Jimenez, Martin, additional, German, Gisela, additional, Gobo Silva, Maria Leticia, additional, Gouin, Francois, additional, Gronchi, Alessandro, additional, Haro‐Varas, Juan Carlos, additional, Jiménez‐Brenes, Natalia, additional, Kasper, Bernd, additional, Lopes de Mello, Celso Abdon, additional, Maki, Robert, additional, Martínez‐Delgado, Paula, additional, Martínez‐Said, Hector, additional, Martinez‐Tlahuel, Jorge Luis, additional, Morales‐Pérez, Jose Manuel, additional, Muñoz‐Casares, Francisco Cristobal, additional, Nakagawa, Suely A., additional, Ortiz‐Cruz, Eduardo Jose, additional, Palmerini, Emanuela, additional, Patel, Shreyaskumar, additional, Moura, David S., additional, Stacchiotti, Silvia, additional, Sunyach, Marie Pierre, additional, Valverde, Claudia M., additional, Waisberg, Federico, additional, and Blay, Jean‐Yves, additional
- Published
- 2020
- Full Text
- View/download PDF
35. Abstract 3767: FBXO32 ubiquitin ligase mediates apoptosis evasion and adaptation to KIT inhibition in gastrointestinal stromal tumor - GIST
- Author
-
Valverde, Alfonso García, primary, Rosell, Jordi, additional, Janeta, Daniel Pilco, additional, Sayols, Sergi, additional, Valverde, Claudia, additional, Esteve, Anna, additional, Gut, Marta, additional, Barretina, Jordi, additional, Demetri, George D., additional, Fletcher, Jonathan A., additional, Carles, Joan, additional, Arribas, Joaquín, additional, and Serrano, César, additional
- Published
- 2020
- Full Text
- View/download PDF
36. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
- Author
-
García-Valverde, Alfonso, primary, Rosell, Jordi, additional, Serna, Garazi, additional, Valverde, Claudia, additional, Carles, Joan, additional, Nuciforo, Paolo, additional, Fletcher, Jonathan A., additional, Arribas, Joaquín, additional, Politz, Oliver, additional, and Serrano, César, additional
- Published
- 2020
- Full Text
- View/download PDF
37. Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus
- Author
-
Álvarez Álvarez, Rosa, primary, Cruz Jurado, Josefina, additional, del Muro Solans, Xavier García, additional, Giner, Javier Lavernia, additional, López Pousa, Antonio, additional, Martín-Broto, Javier, additional, and Valverde, Claudia María, additional
- Published
- 2019
- Full Text
- View/download PDF
38. El cuerpo femenino como territorio sagrado. Una interpretación de la ritualidad sobre la piel entre las indígenas huastecas del oriente de México
- Author
-
Rocha Valverde, Claudia
- Subjects
tatoo ,teenek ,tatuaje ,ancestral ,Mother Earth ,vestimenta ,Madre Tierra ,dress ,fertility ,dhayemlaab ,fertilidad ,sagrado ,sacred - Abstract
Resumen: La Huasteca Potosina es una región al oriente de la república mexicana en la que se desarrollaron pueblos de gran relevancia sociocultural dentro del complejo conocido como Mesoamérica. Este texto se propone un estudio del contexto cosmológico del pueblo huasteco en el culto a distintas deidades entre las que destacaremos el concepto de ‘Madre Tierra’ y su vínculo con la fertilidad. Para ello se analizan distintas formas de representación artística, entre las que destacan los códices, esculturas y vasijas efigie de terracota, a partir de las cuales se plantea la hipótesis de que el cuerpo femenino fue considerado un espacio sagrado adornado con pintura, tatuajes y vestimentas específicas que le dieron identidad simbólica y estética. Abstract: The Huasteca Potosina is a region to the east of Mexico where cultures of great socio cultural relevance developed within a compound known as Mesoamerica. The purpose of this text is to develop a study of the cosmological context of the huasteco people in which such people rendered tribute to different deities, among which we will highlight the concept of Mother Earth and it's link to fertility. For that purpose we consider different artistic ways of representation like codex, sculpure and clay pots from where we propose the feminine body was transformed in a sacred space ornamented with painting, tatoos and specific costumes that gave it a simbolic and aesthetic identity.
- Published
- 2018
39. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS)
- Author
-
Martin-Broto, Javier, primary, Hindi, Nadia, additional, Cruz, Josefina, additional, Martinez-Trufero, Javier, additional, Valverde, Claudia, additional, De Sande, Luis M., additional, Sala, Angeles, additional, Bellido, Lorena, additional, De Juan, Ana, additional, Rubió-Casadevall, Jordi, additional, Diaz-Beveridge, Roberto, additional, Cubedo, Ricardo, additional, Tendero, Oscar, additional, Salinas, Diego, additional, Gracia, Isidro, additional, Ramos, Rafael, additional, Baguè, Silvia, additional, Gutierrez, Antonio, additional, Duran-Moreno, José, additional, and Lopez-Pousa, Antonio, additional
- Published
- 2018
- Full Text
- View/download PDF
40. Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
- Author
-
Alemany, Regina, primary, Moura, David S., additional, Redondo, Andres, additional, Martinez-Trufero, Javier, additional, Calabuig, Silvia, additional, Saus, Carlos, additional, Obrador-Hevia, Antonia, additional, Ramos, Rafael, additional, Villar, Victor H., additional, Valverde, Claudia, additional, Vaz, Maria Angeles, additional, Medina, Javier, additional, Felipe-Abrio, Irene, additional, Hindi, Nadia, additional, Taron, Miguel, additional, and Martin-Broto, Javier, additional
- Published
- 2018
- Full Text
- View/download PDF
41. Territorios, seguridad y soberanía alimentaria. Retos para el futuro
- Author
-
Rocha Valverde, Claudia and Rocha Valverde, Claudia
- Abstract
Esta obra titulada, de manera sugerente, Territorios, seguridad y soberanía alimentaria. Retos para el futuro, está dedicada a la memoria del padre José Barón Larios, en reconocimiento a su trabajo comprometido y amoroso con los indígenas de la Huasteca hidalguense. Fue un religioso apegado a la teología de la liberación y, por lo tanto, activista a favor de los derechos de los más desprotegidos de esa región. Este libro es una compilación de estudios de distintos autores que, de alguna manera, “ponen el dedo en la llaga” al colocarnos frente a los rezagos históricos que la sociedad y el Estado han tenido (y tienen) en distintas regiones indígenas y campesinas del país y de América Latina, que, en el caso de México, se refieren a las Huastecas de San Luis Potosí, Veracruz e Hidalgo, a la Sierra Norte de Puebla, al Totonacapan y a otros enclaves habitados por campesinos negros, como es un caso de estudio en Colombia.
- Published
- 2018
42. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)
- Author
-
Garcia del Muro, Xavier, de Alava, Enrique, Artigas, Vicenç, Bague, Silvia, Braña, Alejandro, Cubedo, Ricardo, Cruz, Josefina, Mulet-Margalef, Nuria, Narvaez, Jose A, Martinez Tirado, Oscar, Valverde, Claudia, Verges, Ramona, Viñals, Joan, Martin-Broto, Javier, Spanish Group for Research on Sarcoma, [Garcia del Muro, Xavier] Inst Catala Oncol Hosp, Barcelona, Spain, [Mulet-Margalef, Nuria] Inst Catala Oncol Hosp, Barcelona, Spain, [de Alava, Enrique] Hosp Univ Virgen del Rocio, Seville, Spain, [Martin-Broto, Javier] Hosp Univ Virgen del Rocio, Seville, Spain, [Artigas, Vicenc] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Bague, Silvia] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Brana, Alejandro] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain, [Cubedo, Ricardo] Hosp Puerta Hierro Majadahonda, Madrid, Spain, [Cruz, Josefina] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain, [Narvaez, Jose A.] Hosp Univ Bellvitge, Barcelona, Spain, [Vinals, Joan] Hosp Univ Bellvitge, Barcelona, Spain, [Martinez Tirado, Oscar] Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain, [Valverde, Claudia] Hosp Univ Vall Hebron, Barcelona, Spain, and [Verges, Ramona] Hosp Univ Vall Hebron, Barcelona, Spain
- Subjects
Cancer Research ,medicine.medical_specialty ,Soft Tissue Neoplasm ,Core-needle-biopsy ,medicine.medical_treatment ,Antineoplastic Agents ,Soft Tissue Neoplasms ,Disease ,Isolated limb perfusion ,030230 surgery ,Toxicology ,Targeted therapy ,03 medical and health sciences ,Inflammatory myofibroblastic tumor ,0302 clinical medicine ,Biopsy ,Multidisciplinary management ,medicine ,Humans ,Pharmacology (medical) ,Doxorubicin plus ifosfamide ,Pharmacology ,Randomized phase-ii ,Soft tissue sarcoma ,medicine.diagnostic_test ,business.industry ,General surgery ,Soft tissue ,Prognostic-factors ,Sarcoma ,Evidence-based medicine ,medicine.disease ,Clear-cell sarcoma ,Surgery ,Solitary fibrous tumor ,Adjuvant chemotherapy ,Treatment ,Oncology ,Chemotherapy, Adjuvant ,Spain ,030220 oncology & carcinogenesis ,Original Article ,business ,Clinical practice guidelines ,High-dose doxorubicin - Abstract
The authors would like to thank Ron Clapp, and GEIS Clinical Research Center for their assistance in the preparation of the manuscript, Garcia Del Muro, X., De Alava, E., Artigas, V., Bague, S., Braña, A., Cubedo, R., Cruz, J., Mulet-Margalef, N., Narvaez, J.A., Martinez Tirado, O., Valverde, C., Verges, R., Viñals, J., Martin-Broto, J.
- Published
- 2015
43. GEIS guidelines for gastrointestinal sarcomas (GIST)
- Author
-
Poveda, Andrés, García Del Muro, Xavier, López-Guerrero, Jose Antonio, Cubedo, Ricardo, Martínez, Virginia, Romero, Ignacio, Serrano, César, Valverde, Claudia, Martín-Broto, Javier, and GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research)
- Subjects
0301 basic medicine ,Oncology ,Indoles ,Pyridines ,medicine.medical_treatment ,Targeted therapy ,chemistry.chemical_compound ,0302 clinical medicine ,Sunitinib ,Molecular Targeted Therapy ,Mesentery ,Gastrointestinal Neoplasms ,Regorafenib ,biology ,GiST ,KIT ,General Medicine ,Combined Modality Therapy ,PDGFRA ,Proto-Oncogene Proteins c-kit ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Imatinib Mesylate ,medicine.drug ,GIST ,medicine.medical_specialty ,Gastrointestinal Stromal Tumors ,Antineoplastic Agents ,CD117 ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Pyrroles ,neoplasms ,GEIS ,business.industry ,Phenylurea Compounds ,Imatinib ,DOG1 ,digestive system diseases ,030104 developmental biology ,chemistry ,biology.protein ,business - Abstract
Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract. They have a characteristic morphology, are generally positive for CD117 (c-kit) and are primarily caused by activating mutations in the KIT or PDGFRA genes(1). On rare occasions, they occur in extravisceral locations such as the omentum, mesentery, pelvis and retroperitoneum. GISTs have become a model of multidisciplinary work in oncology: the participation of several specialties (oncologists, pathologists, surgeons, molecular biologists, radiologists…) has forested advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first effective molecular treatment in solid tumours. Following its introduction, median survival of patients with advanced or metastatic GIST increased from 18 to more than 60months. Sunitinib and Regorafenib are two targeted agents with worldwide approval for second- and third-line treatment, respectively, in metastatic GIST.
- Published
- 2017
44. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib
- Author
-
Serrano, César, primary, García-del-Muro, Xavier, additional, Valverde, Claudia, additional, Sebio, Ana, additional, Durán, José, additional, Manzano, Aránzazu, additional, Pajares, Isabel, additional, Hindi, Nadia, additional, Landolfi, Stefania, additional, Jiménez, Laura, additional, Rubió-Casadevall, Jordi, additional, Estival, Anna, additional, Lavernia, Javier, additional, Safont, María José, additional, Pericay, Carles, additional, Díaz-Beveridge, Roberto, additional, Martínez-Marín, Virginia, additional, Vicente-Baz, David, additional, Vivancos, Ana, additional, Hernández-Losa, Javier, additional, Arribas, Joaquín, additional, and Carles, Joan, additional
- Published
- 2018
- Full Text
- View/download PDF
45. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)
- Author
-
Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Grupo Español de Investigación en Sarcomas, Martín-Broto, Javier, Redondo, Andrés, Valverde, Claudia M., Vaz Salgado, María Ángeles, Mora, Jaume, García del Muro, Xavier, Gutiérrez, Antonio, Tous, Cristina, Carnero, Amancio, Marcilla-Plaza, David, Carranza Carranza, Andrés, Sancho, Pilar, Martínez-Trufero, Javier, Díaz-Beveridge, Robert, Cruz Jurado, Josefina, Encinas-Tobajas, Víctor, Taron Roca, Miguel, Moura, David S., Luna, Pablo, Hindi, Nadia, López-Pousa, Antonio, Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Grupo Español de Investigación en Sarcomas, Martín-Broto, Javier, Redondo, Andrés, Valverde, Claudia M., Vaz Salgado, María Ángeles, Mora, Jaume, García del Muro, Xavier, Gutiérrez, Antonio, Tous, Cristina, Carnero, Amancio, Marcilla-Plaza, David, Carranza Carranza, Andrés, Sancho, Pilar, Martínez-Trufero, Javier, Díaz-Beveridge, Robert, Cruz Jurado, Josefina, Encinas-Tobajas, Víctor, Taron Roca, Miguel, Moura, David S., Luna, Pablo, Hindi, Nadia, and López-Pousa, Antonio
- Abstract
[Background] Patients with relapsed unresectable osteosarcoma represents an unmet need, so active and safe systemic treatments are required. Fas cell surface death receptor and mammalian target of rapamycin pathways are implicated in progressing osteosarcoma, and we had preclinical and clinical experience with a scheme that targets both pathways. Therefore, we designed a phase II trial with gemcitabine plus rapamycin, to determine the efficacy and safety, in this subset of patients., [Patients and methods] A multicenter, single-arm phase II trial was sponsored by the Spanish Group for Research on Sarcoma. Osteosarcoma patients, relapsed or progressing after standard chemotherapy and unsuitable for metastasectomy received gemcitabine and rapamycin p.o. 5 mg/day except for the same day of gemcitabine administration, and the day before. The main end point was 4-month progression-free survival rate (PFSR), with the assumption that rates higher than 40% would be considered as an active regimen. Translational research aimed to correlate biomarkers with the clinical outcome., [Results] Thirty-five patients were enrolled and received at least one cycle. PFSR at 4 months was 44%, and after central radiologic assessment, 2 partial responses and 14 stabilizations (48.5%) were reported from 33 assessable patients. The most frequent grade 3–4 adverse events were: neutropenia (37%), thrombocytopenia (20%), anemia (23%), and fatigue (15%); however, only three patients had febrile neutropenia. Positive protein expression of RRM1 significantly correlated with worse PFS and overall survival, while positivity of P-ERK1/2 was correlated with significant better overall survival., [Conclusion] Gemcitabine plus sirolimus exhibits satisfactory antitumor activity and safety in this osteosarcoma population, exceeding the prespecified 40% of 4-month PFSR. The significant correlation of biomarkers with clinical outcome encourages further prospective investigation.
- Published
- 2017
46. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
- Author
-
Kasper, Bernd, Baumgarten, C., García, J., Bonvalot, Sylvie, Haas, R. L., Haller, F., Hohenberger, Peter, Penel, Nicolas, Messiou, C., van der Graaf, W. T., Gronchi, Alesandro, Bauer, Sebastian, Blay, Jean-Yves, van Coevorden, F., Dileo, P., Dürr, H. R., Fiore, M. R., Grünwald, V., Jones, Robin L., Judson, I., Kettelhack, C., Kopeckova, K., Lazar, A. J., Lindner, Lars H., Martín-Broto, Javier, Rutkowski, Piotr, Stacchiotti, Silvia, Stoeckle, E., Valverde, Claudia M., Verhoef, K., Wardelmann, Eva, Wartenberg, M., Kasper, Bernd, Baumgarten, C., García, J., Bonvalot, Sylvie, Haas, R. L., Haller, F., Hohenberger, Peter, Penel, Nicolas, Messiou, C., van der Graaf, W. T., Gronchi, Alesandro, Bauer, Sebastian, Blay, Jean-Yves, van Coevorden, F., Dileo, P., Dürr, H. R., Fiore, M. R., Grünwald, V., Jones, Robin L., Judson, I., Kettelhack, C., Kopeckova, K., Lazar, A. J., Lindner, Lars H., Martín-Broto, Javier, Rutkowski, Piotr, Stacchiotti, Silvia, Stoeckle, E., Valverde, Claudia M., Verhoef, K., Wardelmann, Eva, and Wartenberg, M.
- Abstract
Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals’ AND patients’ expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.
- Published
- 2017
47. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
- Author
-
Joensuu, Heikki, primary, Blay, Jean-Yves, additional, Comandone, Alessandro, additional, Martin-Broto, Javier, additional, Fumagalli, Elena, additional, Grignani, Giovanni, additional, Del Muro, Xavier Garcia, additional, Adenis, Antoine, additional, Valverde, Claudia, additional, Pousa, Antonio Lopez, additional, Bouché, Olivier, additional, Italiano, Antoine, additional, Bauer, Sebastian, additional, Barone, Carlo, additional, Weiss, Claudia, additional, Crippa, Stefania, additional, Camozzi, Maura, additional, Castellana, Ramon, additional, and Le Cesne, Axel, additional
- Published
- 2017
- Full Text
- View/download PDF
48. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).
- Author
-
Martin‐Broto, Javier, Hindi, Nadia, Cruz, Josefina, Martinez‐Trufero, Javier, Valverde, Claudia, De Sande, Luis M., Sala, Angeles, Bellido, Lorena, De Juan, Ana, Rubió‐Casadevall, Jordi, Diaz‐Beveridge, Roberto, Cubedo, Ricardo, Tendero, Oscar, Salinas, Diego, Gracia, Isidro, Ramos, Rafael, Baguè, Silvia, Gutierrez, Antonio, Duran‐Moreno, José, and Lopez‐Pousa, Antonio
- Subjects
BIOPSY ,CANCER chemotherapy ,REPORTING of diseases ,HEALTH facilities ,LONGITUDINAL method ,SARCOMA ,SOFT tissue tumors ,TUMOR classification ,TREATMENT effectiveness ,PREOPERATIVE period ,PERIOPERATIVE care ,TUMOR risk factors ,CANCER risk factors - Abstract
Background: Reference centers (RCs) are a key point for improving the survival of patients with soft‐tissue sarcomas (STS). The aim of this study was to evaluate selected items in the management of patients with STS, comparing results between RC and local hospitals (LHs). Materials and Methods: Diagnostic and therapeutic data from patients diagnosed between January 2004 and December 2011 were collected. Correlation with outcome was performed. Results: A total of 622 sarcomas were analyzed, with a median follow‐up of 40 months. Imaging of primary tumor preoperatively (yes vs. no) correlated with a higher probability of free surgical margins (77.4% versus 53.7%; p =.006). The provenance of the biopsy (RC vs. LH) significantly affected relapse‐free survival (RFS; 3‐year RFS 66% vs. 46%, respectively; p =.019). Likewise, 3‐year RFS was significantly worse in cases with infiltrated (55.6%) or unknown (43.4%) microscopic surgical margins compared with free margins (63.6%; p <.001). Patients managed by RCs had a better 3‐year overall survival compared with those managed by LHs (82% vs. 70.4%, respectively; p =.003). Perioperative chemotherapy in high‐risk STS, more frequently administered in RCs than in LHs, resulted in significantly better 3‐year RFS (66% vs. 44%; p =.011). In addition, patients with stage IV disease treated in RCs survived significantly longer compared with those in LHs (30.4 months vs. 18.5 months; p =.036). Conclusion: Our series indicate that selected quality‐of‐care items were accomplished better by RCs over LHs, all with significant prognostic value in patients with STS. Early referral to an RC should be mandatory if the aim is to improve the survival of patients with STS. Implications for Practice: This prospective study in patients diagnosed with soft‐tissue sarcoma shows the prognostic impact of reference centers in the management of these patients. The magnitude of this impact encompasses all steps of the process, from the initial management (performing diagnostic biopsy) to the advanced disease setting. This is the first prospective evidence showing improvement in outcomes of patients with metastatic disease when they are managed in centers with expertise. This study provides extra data supporting referral of patients with sarcoma to reference centers. Management of soft‐tissue sarcoma is challenging. This article reports on sarcoma clinical management in cancer centers in Spain, based on information from a prospective registry launched by the Spanish Group for Research in Sarcoma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
49. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
- Author
-
Serrano, César, García‐del‐Muro, Xavier, Valverde, Claudia, Sebio, Ana, Durán, José, Manzano, Aránzazu, Pajares, Isabel, Hindi, Nadia, Landolfi, Stefania, Jiménez, Laura, Rubió‐Casadevall, Jordi, Estival, Anna, Lavernia, Javier, Safont, María José, Pericay, Carles, Díaz‐Beveridge, Roberto, Martínez‐Marín, Virginia, Vicente‐Baz, David, Vivancos, Ana, and Hernández‐Losa, Javier
- Subjects
GASTROINTESTINAL tumors ,CYTOGENETICS ,SARCOMA ,DRUG side effects ,SYMPTOMS ,TREATMENT effectiveness ,TREATMENT duration ,CANCER patients ,METASTASIS ,CONNECTIVE tissue tumors ,LONGITUDINAL method ,IMATINIB ,GENETIC mutation ,DISEASE progression - Abstract
Background: Oncogenic KIT/PDGFRA signaling inhibition with imatinib achieves disease control in most patients with advanced/metastatic gastrointestinal stromal tumor (GIST), but resistance eventually develops after 20–24 months. Notably, a small subset of these patients obtain durable benefit from imatinib therapy. Methods: We analyzed clinical, pathological, and molecular characteristics and long‐term outcomes in patients with metastatic GIST treated with continuous daily dosing of frontline imatinib in a cohort of patients benefiting for ≥5 years. A control group was obtained from the national Spanish Group for Sarcoma Research database and used as comparator. Results: Sixty‐four imatinib long‐term responders (LTRs) and 70 control cases were identified. Compared with controls, LTRs at baseline had better performance status (PS) 0–1 (100% vs. 81%), lower mitotic count (median, 8 vs. 15), and tumor burden (number of metastases, 3 vs. 7). KIT exon 11 was the only region found mutated in LTRs. LTRs achieved 34% complete responses and a median progression‐free survival of 11 years, compared with 4% and 2 years, respectively, in the control cohort. Prognostic factors that independently predicted long‐term benefit with imatinib were PS, number of metastases prior to imatinib, and response to imatinib. Fifteen LTR patients developed new side effects attributable to imatinib after ≥5 years of continuous treatment. No resistance mutations were found in metastatic samples from three patients progressing on imatinib. Conclusion: GISTs in LTRs are a distinctive entity with less aggressive behavior and marked sensitivity to KIT inhibition. Patients reaching 5 or more years on imatinib have a higher chance of remaining progression free over time. Implications for Practice: This work demonstrates that clinical and inherent tumor characteristics define a subset of patients with gastrointestinal stromal tumor (GIST) with increased likelihood to achieve durable response to first‐line imatinib therapy. Patients reaching ≥5 years on imatinib have a greater chance of remaining progression free over time, although the disease is unlikely to be cured. Imatinib is well tolerated for >5 years, and emergent toxicities are overall manageable. Resistance to imatinib emerging in patients with GISTs after long‐term imatinib treatment does not involve polyclonal expansion of KIT secondary mutations. This article identifies distinctive clinicopathological and molecular features in long‐term responders to imatinib treatment compared with patients with gastrointestinal stromal tumors reaching the usual median progression‐free survival. Clinical insights from this subgroup collected during the long‐term follow‐up are also provided. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
50. SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)
- Author
-
López-Pousa, Antonio, Martín-Broto, Javier, Martínez-Trufero, Javier, Sevilla, I., Valverde, Claudia M., Álvarez, R., Carrasco-Álvarez, J. A., Cruz Jurado, Josefina, Hindi, Nadia, García del Muro, Xavier, López-Pousa, Antonio, Martín-Broto, Javier, Martínez-Trufero, Javier, Sevilla, I., Valverde, Claudia M., Álvarez, R., Carrasco-Álvarez, J. A., Cruz Jurado, Josefina, Hindi, Nadia, and García del Muro, Xavier
- Abstract
Soft-tissue sarcomas are uncommon and heterogeneous tumors of mesenchymal origin. A soft-tissue mass that is increasing in size, greater than 5 cm, or located under deep fascia are criteria for suspicion of sarcoma. Diagnosis, treatment, and management should preferably be performed by a multidisciplinary team in reference centers. MRI and lung CT scan are mandatory for local and distant assessment. A biopsy indicating histological type and grade is needed previous to the treatment. Wide surgical resection with tumor-free tissue margin is the primary treatment for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not likely of being improved with reexcision. Neoadjuvant and adjuvant chemotherapy improve survival in selected cases, usually in high-grade sarcomas of the extremities. In the case of metastatic disease, patients with exclusive lung metastasis could be considered for surgery. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. New drugs have shown activity in second-line therapy and in specific histological subtypes.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.